X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
MEM-ANT3310 combines the well-known carbapenem meropenem (MEM) with ANT3310, a breakthrough serine-beta-lactamase (SBL) inhibitor.
Lead Product(s): ANT3310,Meropenem
Therapeutic Area: Infections and Infectious Diseases Product Name: MEM-ANT3310
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
SYN-004 (ribaxamase), is an oral prophylactic therapy designed to degrade certain IV beta-lactam antibiotics within GI tract, thereby preventing antibiotic-mediated damage to the gut microbiome and reducing adverse outcomes associated with antibiotic-mediated gut dysbiosis.
Lead Product(s): Ribaxamase,Meropenem
Therapeutic Area: Immunology Product Name: SYN-004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
ORAvance (Xeruborbactam) an orally-administered combination product that delivers xeruborbactam to treat infections that occur in outpatient and community setting caused by drug-resistant gram-negative bacteria.
Lead Product(s): Xeruborbactam,Meropenem
Therapeutic Area: Infections and Infectious Diseases Product Name: ORAvance
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
The combined cash of the two companies is expected to provide runway into Q3 2023, funding the advancement of Aceragen’s pipeline, including ACG-701 (sodium fusidate) and ACG-801, through important 2023 clinical milestones.
Lead Product(s): Sodium Fusidate,Ceftazidime,Meropenem
Therapeutic Area: Infections and Infectious Diseases Product Name: ACG-701
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Idera Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 28, 2022
Details:
Under the License Agreement, SciClone will be responsible for conducting and funding local clinical development as well as commercialization of Vaborem® (meropenem). To facilitate patients in China, SciClone will conduct local clinical trials and pursue approvals in China.
Lead Product(s): Meropenem,Vaborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Vaborem
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SciClone
Deal Size: $113.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 20, 2022
Details:
It appears from nonclinical data that KSP-1007 broadly and strongly inhibits β-lactamases, which are enzymes that are produced by bacteria that can degrade carbapenem antibiotics. Sumitovant is leading the program of the compound in the U.S.
Lead Product(s): KSP-1007,Meropenem
Therapeutic Area: Infections and Infectious Diseases Product Name: KSP-1007
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sumitomo Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2022
Details:
The funding for Antabio will allow to continue the development of ANT3310 towards clinical studies and reach crucial milestones such as the clinical demonstration of its safety and tolerability in humans.
Lead Product(s): ANT3310,Meropenem
Therapeutic Area: Infections and Infectious Diseases Product Name: ANT3310
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Funding January 06, 2022
Details:
Under the terms of the deal, Hikma will responsible for the registration and commercialization of Orbactiv and Vabomere across its 18 MENA markets. This extends Hikma’s existing partnership with Melinta for their intravenous and oral formulations of Baxdela.
Lead Product(s): Meropenem,Vaborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Vabomere
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hikma Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 29, 2021
Details:
QIDP is granted to Antabio's MEM-ANT3310 for major hospital indications including nosocomial pneumonia.
Lead Product(s): ANT3310,Meropenem
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
